home1_b

TRIANNI and Antibody Discovery

Fully human monoclonal antibodies are powerful biological therapeutics.

Among many options available for isolating them, TRIANNI’s technology is distinguished by key advantages of ease of use, antibody diversity, and in vivo selection.

partnering
events

PEGS Korea

September 20–22 | Seoul, South Korea

7th Annual World Bispecifc

PARTNER | September 27–29 | Boston, MA

BioJapan 2016

October 12-14 | Pacifico Yokohama, Japan

September 13–15 | Boston, MA